Dr. Tindle’s clinical research has been continually funded by the NIH since 2002. A major strength of this body of work has been the synergy of research, clinical, and quality improvement data that our team translates directly into improved patient care. To this end, the clinical Tobacco Treatment Service (detailed below) facilitates NIH-funded clinical trials and QI projects:
- Metabolism Informed Smoking Treatment (MIST) RCT (R01 CA232516)
- Helping HAND 4 (HH4) (R01 HL111821)
- Integrating Comprehensive Precision Tobacco Treatment for Patients with Cancer (P30CA068485-22S3)
- Investigating N-3 Fatty Acids to prevent Neonatal Tobacco-related outcomeS (INFANTS) PIs: Murff and Tindle; R01HD098719)
For the MIST and INFANTS trials, TTS counselors serve as an “expertise on call” resource for study staff in determining participant eligibility, conducting phone counseling, and fielding smoking-related questions from participants during follow up. Historically, Dr. Tindle and members of the ViTAL Center have participated in a PI or MPI role in other clinical trials supported by NIDA, NIAAA, and NHLBI. These include productive collaborations with the Tennessee Center for AIDS Research (CFAR) to foster research advancing substance use treatment in people living with HIV (U01-AA020780). These trials, in combination with leveraging large datasets including the Framingham Heart Study, The Women’s Health Initiative, The Southern Community Cohort Study to name a few, provide a rich environment to support trainees in pursuit of their research questions.
Please visit our Publications page to view more detailed information on Dr. Tindle's research.